Analysts at Guggenheim Securities initiated coverage on Merrimack Pharmaceuticals Inc MACK with a Buy rating.
The target price for Merrimack Pharmaceuticals is set to $15.
Merrimack Pharmaceuticals shares have gained 72.46 percent over the past 52 weeks, while the S&P 500 index has surged 11.15 percent in the same period.
Merrimack Pharmaceuticals' shares fell 0.52 percent to $11.46 in after-hours trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in